Bristol Myers Squibb (CELG-RI) Assets Growth (5y) (2014 - 2026)

Bristol Myers Squibb (CELG-RI) Assets Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.11%
Dec 31, 2025 -5.34%
Sep 30, 2025 -5.05%
Jun 30, 2025 -5.86%
Mar 31, 2025 -6.49%
Dec 31, 2024 -6.55%
Sep 30, 2024 10.28%
Jun 30, 2024 11.40%
Mar 31, 2024 23.24%
Dec 31, 2023 22.15%
Sep 30, 2023 22.02%
Jun 30, 2023 23.42%
Mar 31, 2023 23.30%
Dec 31, 2022 23.61%
Sep 30, 2022 23.65%
Jun 30, 2022 24.61%
Mar 31, 2022 25.62%
Dec 31, 2021 26.53%
Sep 30, 2021 26.88%
Jun 30, 2021 27.54%